Future directions in SMA treatment involve incorporating SMN-independent therapies alongside SMN-dependent ones to provide broader benefits, especially for patients diagnosed later or with milder forms of SMA. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.